SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals ($CRML) is trending due to speculation around potential U.S. government investment in its Greenland rare earths mine, spurred by reports of government interest and comparisons to similar deals involving other companies. The community is discussing the potential impact of government backing, particularly a possible equity stake, and how this could affect the valuation of $CRML and its majority owner, European Lithium ($EULIF). Some are also focused on warrant prices and trading strategies around potential price spikes.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the crypto market shows signs of a rally, with Bitcoin hitting new highs. Community members are actively discussing potential price targets and whether ETH can outperform BTC, while also considering factors like institutional adoption and upcoming catalysts.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is surging to new all-time highs, triggering excitement and discussions about potential targets like $130k-$150k this week. Community members are attributing the rally to factors like a potential supply shortage, institutional buying, and the start of 'Uptober', while also speculating about a possible short squeeze. Many are also pointing to Bitcoin's role as a safe haven amid economic uncertainty.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as the community discusses the upcoming California International Air Show, where the company plans to conduct public flights of its Midnight aircraft. Community members are debating the likelihood of Archer demonstrating vertical take-off and landing capabilities at the event, with some expressing concerns about potential delays in FAA approval. Bullish sentiment is fueled by potential catalysts like military contracts and partnerships, while bears cite a lack of revenue and unproven eVTOL technology.

VivoPower International Plc is a sustainable energy solutions company, which engages in the customers with turnkey decarbonization solutions that enable them to achieve net zero carbon status. It operates through the following segments: Critical Power Services, Electric Vehicles, Sustainable Energy Solutions, Solar Development, and Corporate Office. The Critical Power Services segment focuses on the design, supply, installation, and maintenance of critical power, control and distribution systems, including for solar farms. The Electric Vehicles segment delivers electric vehicles for mining and other rugged industrial customers. The Sustainable Energy Solutions segment refers to the design, evaluation, sale, and implementation of renewable energy infrastructure to customers both on a standalone basis and in support of Tembo Electric Vehicles. The Solar Development segment represented by caret comprises of 12 solar projects in the US. The Corporate Office segment includes the company’s corporate functions, which refers to the costs to maintain Nasdaq listing, comply with applicable SEC reporting requirements, and related investor relations. The company was founded by Tser Fah Chin on February 1, 2016 and is headquartered in London, the United Kingdom.

VivoPower International PLC

VVPR is trending due to its announced plan to acquire Ripple shares, aiming for significant XRP exposure at a discounted rate, which has sparked excitement and debate within the investment community. Community members are actively discussing the potential impact of this move on VVPR's valuation and its alignment with the broader XRP ecosystem. Some are optimistic about the potential gains, while others express skepticism about the company's strategy and execution.

Loews Corp. is a holding company, which engages in the business of commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, and operation of a chain of hotels. It operates through the following segments: CNA Financial, Boardwalk Pipelines, Loews Hotels and Co, and Corporate. The CNA Financial segment is involved in the sale of property and casualty insurance products and services, including surety, primarily through a network of independent agents, brokers, and managing general underwriters. The Boardwalk Pipelines segment focuses on midstream portion of the natural gas and NGLs industry, providing transportation, and storage for those commodities. The Loews Hotels and Co segment refers to a chain of hotels, which are in the United States and one of which is in Canada. The Corporate segment consists of investment income from the parent company’s cash and investments, parent company interest expense, and other unallocated parent company expenses. The company was founded by Laurence A. Tisch and Preston Robert Tisch on November 12, 1969 and is headquartered in New York, NY.

Loews Corp.

Loews Corp ($L) is trending due to recent unusual options activity and discussion of potential growth drivers. Community members are actively discussing call options with various expiration dates, alongside potential catalysts such as infrastructure spending and the growth of renewable energy companies, while others point to chart distribution patterns. The stock is also being evaluated for its diversified play with strong insurance and energy segments.

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT ($LASR) is trending due to increased interest in laser weapon technology and potential involvement in defense projects like the "Golden Dome." Community members are discussing unusual options activity and anticipating contract news, particularly related to defense applications. The stock has also seen upgrades from analysts, contributing to the heightened attention.

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Kymera Therapeutics Inc

Shares of Kymera Therapeutics are moving due to positive results from a Phase 1 clinical trial of KT-474, leading Sanofi to advance the drug. Community members are discussing the potential of Kymera's targeted protein degradation platform and its implications for immunology and oncology. Analyst ratings have been updated, with some highlighting the company's innovative approach and pipeline potential.

Logitech International SA is a holding company, which engages in the design of software-enabled hardware solutions. Its portfolio includes gaming, keyboards and combos, pointing devices, video collaboration, webcams, tablet accessories, and headsets. Its cloud based services includes video conferencing platforms, esports or video games, music streaming platforms, content streaming platforms, and and creativity and productivity platforms. It enhances through software, including machine learning and artificial intelligence. The company was founded by Daniel Borel, Pierluigi Zappacosta, and Giacamo Marini on October 2, 1981 and is headquartered in Lausanne, Switzerland.

Logitech International S.A.

Logitech is trending as investors digest news of a C-suite transition and evaluate the company's prospects. The community is discussing the potential impact of the recent executive changes on Logitech's strategic direction. Mixed sentiment is reflected in options activity, with both bullish and bearish positions being taken, while some analysts adjust their price targets.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

AXON is trending amid discussions about its growth potential, particularly in software and services, and anticipation for upcoming earnings. Community members are analyzing unusual options activity, debating valuation, and evaluating potential impacts from AI integration and new product releases. Bullish sentiment is fueled by strong recurring revenue streams and potential expansion into new markets, while bearish concerns include valuation and market volatility.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?

KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.

Shares of Abeona Therapeutics Inc. (ABEO) were in the spotlight on Tuesday afternoon after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.abeonatherapeutics.com/press-releases/detail/303/u-s-fda-approves-zevaskyn-prademagene-zamikeracel">announced</a> that the U.S. Food and Drug Administration (FDA) has approved its gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic skin disease with no known cure caused by a defect in the COL7A1 gene that leaves them unable to produce functioning type VII collagen.Patients with the disease have fragile skin characterized by extensive blistering and severe wounds that often cover more than 30% of the body surface. These wounds are difficult to heal, can remain open for years, and many that do close tend to reopen.Abeona stated that its ZEVASKYN sheet is the only FDA-approved product for treating RDEB wounds with a single application.ZEVASKYN consists of a patient’s skin cells that have been genetically modified to produce functional Type VII collagen. These sheets are then surgically applied to the patient’s wounded areas.Up to 12 credit card-sized sheets can be joined together to cover large areas in a single application, the company said.ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers (QTCs), which are treatment centers located across the U.S. with experience in cell and gene therapy.However, H.C. Wainwright stated on Tuesday that it does not expect ZEVASKYN to have an immediate impact on Krystal Biotech’s Vyjuvek. Vyjuvek is a topical gel aimed at wound healing in patients with dystrophic epidermolysis bullosa.Vyjuvek remains the "differentiated opportunity, particularly with regard to cost, surface area coverage for wound healing and quality of life/convenience," the analyst told investors in a research note, as per TheFly.<a href="https://stocktwits.com/symbol/ABEO">ABEO stock</a> is down by about 16% this year but up by over 44% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/paypal-flags-uncertainty-in-global-macro-environment/chQ6JJNRbLW">PayPal Reports Better-Than-Expected Q1 Earnings But Flags Uncertainty In Global Macro Environment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease

ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers, located across the U.S. with experience in cell and gene therapy.

Equity

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Abeona Therapeutics Inc. (Abeona or the Company...

The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ: ABEO) on behalf of investors concerning the Companys possible violations of...

Abeona Therapeutics announces employee inducement grants

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.28	--	--	N/A
Q2 '25	-$0.39	$1.71	538.46%	BEAT
Q1 '25	-$0.36	-$0.24	32.96%	BEAT
Q4 '24	-$0.35	$0.50	243.68%	BEAT
Q3 '24	-$0.39	-$0.63	-60.51%	MISSED

ABEO
Abeona Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ABEO News

ABEO Abeona Therapeutics Inc